ESCLEROSIS MÚLTIPLE
Royal Hobart Hospital
Hobart, AustraliaPublicaciones en colaboración con investigadores/as de Royal Hobart Hospital (2)
2023
-
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713
2022
-
Confirmed disability progression as a marker of permanent disability in multiple sclerosis
European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334